secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0000950170-23-066250
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca prioritizes pipeline, extends cash runway to H1 2026; FDA/EMA agree on Phase 3 naporafenib trial
--------------------------------------------------------------------------------

- FDA/EMA endorsed SEACRAFT-2 Phase 3 design for naporafenib+trametinib in NRASm melanoma; dual primary endpoints PFS and OS.
- Phase 1 data for ERAS-801 in rGBM: MTD 240 mg QD, safe, PK above 90% tumor growth inhibition; expansion cohorts enrolling.
- Deprioritized FLAGSHP-1 (ERAS-601+cetuximab), ERAS-5, ERAS-10; cash runway extended from H2 2025 to H1 2026.
- Key upcoming milestones: naporafenib Phase 1b data in RAS Q61X tumors (2H 2024), ERAS-007 combo data in BRAFm CRC (H2 2023–H1 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023066250/0000950170-23-066250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023066250/eras-20231128.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-066250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer